Alport Foundation of Australia
 

Privacy Policy             Disclaimer            Sitemap         Copyright ® 2010 Alport Foundation of Australia, Inc. All Rights Reserved 

Graphic kindly provided by Zygote Media Group, Inc.    www.Zygote.com     www.3DScience.com          Alport Foundation of Australia: ABN 87 956 459 275

Expert Guidelines for the Management of Alport

Syndrome and Thin Basement Membrane Nephropathy

Judy Savige(1), Martin Gregory(2),  Oliver Gross(3),  Clifford Kashtan(4), Jie Ding(5),  and Frances Flinter(6)


1.Department of Medicine (Northern Health), University of Melbourne, Melbourne, Australia;

2.Division of Nephrology, University of Utah School of Medicine, Salt Lake City, Utah;

3.Department of Nephrology and Rheumatology, University Medicine Goettingen, Germany;

4.Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota;

5.Pediatric Department, Peking University First Hospital, Beijing, China;

6.Department of Clinical Genetics, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.

ABSTRACT

Few prospective, randomised controlled clinical trials address the diagnosis and management of patients with Alport syndrome or thin basement membrane nephropathy. Adult and pediatric nephrologists and geneticists from four continents whose clinical practice focuses on these conditions have developed the following guidelines.

The 18 recommendations are based on Level D (Expert opinion without explicit critical appraisal, or based on physiology, bench research, or first principles—National Health Service category) or Level III (Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees—U.S. Preventive Services Task Force) evidence.

The recommendations include:

  1. the use of genetic testing as the gold standard for the diagnosis of Alport syndrome and the demonstration of its mode of inheritance;

  2. the need to identify and follow all affected members of a family with X-linked Alport syndrome, including most mothers of affected males;

  3. the treatment of males with X-linked Alport syndrome and individuals with autosomal recessive disease with renin-angiotensin system blockade, possibly even before the onset of proteinuria;

  4. discouraging the affected mothers of males with X-linked Alport syndrome from renal donation because of their own risk of kidney failure;

  5. consideration of genetic testing to exclude X-linked Alport syndrome in some individuals with thin basement membrane nephropathy.

The authors recognise that as evidence emerges, including data from patient registries, these guidelines will evolve further.

J Am Soc Nephrol 24: 364–375, 2013. doi: 10.1681/ASN.2012020148

DOWNLOAD THE ENTIRE ARTICLE AND THE 18 RECOMMENDATIONS IN DETAIL
 pdf formatEXPERT_GUIDELINES_files/Expert%20guidelines%20for%20AS.pdf